CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.

Overview of attention for article published in Journal of Clinical Oncology, June 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 3 news outlets
twitter: 2 X users

patent: 2 patents
guideline: 1 clinical guideline source

Readers on

mendeley: 17 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,135 followers.

RT @cancer_evolve: DRUG TARGETS: early data show proof of concept that tumours harbouring NRG1 fusions are sensitive to ERBB3 inhibition, w…

DRUG TARGETS: early data show proof of concept that tumours harbouring NRG1 fusions are sensitive to ERBB3 inhibition, with an anti-ERBB3 antibody seribantumab delivering 3 responses in 10 patients, including 1 CR. https://t.co/qLcB7CHE53

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.